Landmark Study In The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence
Posted by: DrugsNews on: 12 Nov, 2009
Landmark Study In The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence
An analysis conducted by the Finnish Breast Cancer Group and published in The Lancet Oncology shows women at intermediate to high-risk of early breast cancer recurrence who received capecitabine as part of their chemotherapy regimen had a 34% reduction in the risk of the disease returning or death, compared with those taking the chemotherapy combination regimen without capecitabine.
Read more about Landmark Study In The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence
| Indian Pharmacy Online! Looking for Generic Medications? Quality Drugs at affordable prices! Reliable Indian Pharmacy www.IndianPharmacy.org |
#1 Canadian Pharmacy Online! The Lowest Prices from Canadian Drugstore! Various payments, secure shopping, worldwide shipping! www.CanadianPharmacyLtd.org |
What are the Drugs-Review websites?
The Drugs-Review websites are NOT but will be your number one stop for all the latest news, comment and pharmaceutical industry information.
Random Posts
Related posts:
- Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda) Combination Therapy Reduces Early Breast Cancer Recurrence
- Alcohol Ups Risk of Breast Cancer Recurrence
- M. D. Anderson News Release: Early Stage, HER2 Positive Breast Cancer Patients at Increased Risk of Recurrence
